U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06937996) titled 'Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-' on April 11.
Brief Summary: The purpose of this study is to evaluate the short and intermediate term safety of the NanoKnife Irreversible Electroporation System when used off-label to treat unresectable pancreatic cancer. In addition, the study will evaluate the efficacy of this device in treating pain associated with unresectable pancreatic cancer. Quality of life post-procedure will also be collected.
Study Start Date: May 31
Study Type: OBSERVATIONAL
Condition:
Pancreatic Cancer Non-resectable
Intervention:
DEVI...